Viracta Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston, MD, President and Chief Executive Officer of Viracta, will present a corporate overview at the H.C. Wainwright 22(nd) Annual Global Investment Conference on Tuesday, September 15, 2020 at 3:00 pm ET.

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company targeting virus-associated malignancies. The Company's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphomas. Viracta is pursuing application of this kick and kill approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma and gastric carcinoma, and other viral-related cancers.

For additional information please visit

Media and Investor Contact:

Amy Conrad
Juniper Point

Joyce Allaire
LifeSci Advisors
(212) 915-2569

View original content to download multimedia:

SOURCE Viracta